Pifenate

Pifenate

SCHEMBL2730331

CCOC(=O)C(CC1CCCCN1)(c1ccccc1)c1ccccc1

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 6/20 0.49
SLC6A2 P23975 4/20 0.49
SLC6A4 P31645 3/20 0.49
ALDH1A1 P00352 2/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.43
CHRM2 P08172 2/20 0.41
CHRM1 P11229 2/20 0.41
CHRM3 P20309 2/20 0.41
CHRM4 P08173 1/20 0.41
DHFR P00374 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
TSHR P16473 1/20 0.40
NFKB1 P19838 1/20 0.40
CYP2C19 P33261 1/20 0.40
SCN1A P35498 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22260067 0.73 POLB (0.51) POLBCYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL20833001 0.73 POLB (0.51) POLBCYP1A2CYP2D6CYP2C19RAB9A
SCHEMBL28970082 0.72 CHRM2 (0.65) ALDH1A1MAPTPOLBCHRM2CHRM1
SCHEMBL678496 0.72 KDM4E (0.41) POLBCHRM2CHRM1CHRM3CYP1A2
SCHEMBL8633173 0.71 SLC6A3 (0.43) SLC6A3SLC6A2SLC6A4POLBDHFR
SCHEMBL8633167 0.71 SLC6A3 (0.43) SLC6A3SLC6A2SLC6A4POLBDHFR
SCHEMBL8880729 0.71 KMT2A (0.47) POLBCHRM2CHRM1CHRM3LMNA
SCHEMBL4885111 0.70 ALDH1A1 (0.50) SLC6A3SLC6A2ALDH1A1MAPTPOLB
SCHEMBL465843 0.70 POLB (0.48) SLC6A3SLC6A2SLC6A4POLBCYP1A2
Hydrochloric Acid SCHEMBL8879883 0.70 KMT2A (0.49) POLBCHRM2CHRM1CHRM3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8454582-B2 Methods and devices for the treatment of ocular conditions SURMODICS, INC. (US) 2013-06-04 US disclosed
US-20110159073-A1 METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS DEJUAN EUGENE 2011-06-30 US disclosed
US-20060110428-A1 Methods and devices for the treatment of ocular conditions SURMODICS MD, LLC 2006-05-25 US disclosed
WO-2006014484-A2 METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS SURMODICS, INC. (US) 2006-02-09 WO disclosed
US-20050002865-A1 Diagnostic/therapeutic agents AMERSHAM HEALTH AS (NO) 2005-01-06 US disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-6680047-B2 FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2004-01-20 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-20020102217-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6331289-B1 ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED NYCOMED IMAGING AS (NO) 2001-12-18 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed
US-5232484-A Aqueous acid solution; mineralization; absence of large concentrations of organic solvents, chloride and sulfate THE CONNECTICUT AGRICULTURAL EXPERIMENT STATION (US) 1993-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 SLC6A3 3135/4885SLC6A2 2841/4885SLC6A4 3426/4885
US-20050002865-A1 Diagnostic/therapeutic agents FUS, HNRNPF, HNRNPR SLC6A3 3142/4885SLC6A2 3073/4885SLC6A4 3449/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 SLC6A3 2768/4885SLC6A2 2713/4885SLC6A4 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.